Necrotizing Fasciitis
13
0
1
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.7%
1 terminated out of 13 trials
90.0%
+3.5% vs benchmark
15%
2 trials in Phase 3/4
33%
3 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (13)
AFS Compared to AHC in Treatment of Necrotizing Fasciitis NF
RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction
Coagulation and Fibrinolysis as Virulence Factors for Invasive Staphylococcus Aureus and Streptococcus Infections
SKin and Soft Tissue Necrotizing INfections in the Intensive Care Unit: a Prospective Multi-national Cohort Study
Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections
Modulation of Biomarkers in Patients With Flesh-eating Bacterial Infections After With Hyperbaric Oxygen Treatment
Hyperglycemia in Surgical Infections
Severe Soft Tissue Infections: Perspectives of Patients and Significant Others
Systems Medicine to Study Necrotizing Soft Tissue Infections (NSTIs).
Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial
Biomarkers in Patients With Flesh-eating Bacterial Infections
Klebsiella Pneumoniae Necrotizing Fasciitis: Clinical and Microbiological Features
Outcome and Related Factors of Necrotizing Fasciitis of the Limb